Please ensure Javascript is enabled for purposes of website accessibility

Why Lantheus Stock Is Soaring Today

By Keith Speights - May 27, 2021 at 11:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are cheering FDA approval for the company's prostate cancer imaging agent.

What happened

Shares of Lantheus Holdings (LNTH -0.23%) were soaring 17.1% as of 11:01 a.m. EDT on Thursday. The big jump came after the company announced that the Food and Drug Administration had approved Pylarify, an imaging agent used to identify prostate cancer.

So what

Today's significant gain for the life sciences stock underscores how optimistic investors are about the market potential for Pylarify. It's the first imaging agent to win FDA approval that's targeted to the prostate-specific membrane antigen (PSMA) for use in positron emission tomography.

Doctor standing next to a male patient about to go through a medical imaging scan

Image source: Getty Images.

Lantheus thinks that Pylarify could represent "a paradigm shift" in how metastasized or recurrent prostate cancer is identified. CEO Mary Anne Heino said that the company believes the imaging agent could provide "more accurate and earlier detection of disease than conventional imaging."

Now what

Lantheus plans to make Pylarify available immediately in parts of the mid-Atlantic region as well as in the southern U.S. The company expects that availability of the product will expand rapidly to other areas across the country over the next six months.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lantheus Holdings, Inc. Stock Quote
Lantheus Holdings, Inc.
$83.15 (-0.23%) $0.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.